Current disease status-Recurrent cancer Posts on Medivizor
Navigation Menu

Current disease status-Recurrent cancer Posts on Medivizor

Is the biosimilar drug ABP 125 as effective as bevacizumab in patients with lung cancer?

Posted by on Jan 17, 2019 in Lung cancer | 0 comments

In a nutshell This study examined how safe and effective is biosimilar ABP 215 in non-small cell lung cancer (NSCLC), compared to bevacizumab (Avastin). This study concluded that this drug is as safe and effective as bevacizumab in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung...

Read More

Re-treatment with cetuximab improves cancer outcomes in patients with inoperable colorectal cancer

Posted by on Dec 23, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effect of cetuximab (Erbitux) in patients with metastatic (spread to other parts of the body) colorectal cancer who did not respond to initial cetuximab treatment. Researchers suggested that this treatment may be beneficial in longer treatment durations. Some background The standard treatment for patients...

Read More

Rectal cancer: short- and long-term outcomes of robotic assisted laparoscopic surgery

Posted by on Dec 12, 2018 in Colorectal cancer | 0 comments

In a nutshell This article investigated the short- and long-term outcomes of patients with rectal cancer who underwent robotic-assisted laparoscopic surgery (RALS). The authors concluded that RALS is beneficial and has good short- and long-term outcomes.  Some background Conventional laparoscopic surgery (CLS; involves small cuts...

Read More

Which treatment works best, nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone for advanced melanoma

Posted by on Nov 7, 2018 in Melanoma | 0 comments

In a nutshell This study wanted to find out which medications are better for treating advanced melanoma; nivolumab (Opdivo) plus ipilimumab (Yervoy), nivolumab alone, or ipilimumab alone. The study found that using the combination of nivolumab and ipilimumab was more effective than using nivolumab alone, with the least...

Read More

Comparing different chemotherapy combinations to improve treatment of extensive-stage small cell lung cancer

Posted by on Sep 28, 2018 in Lung cancer | 0 comments

In a nutshell This study looked at a combination of irinotecan (Camptosar) and platinum-based drugs, for treating patients with extensive-stage small cell lung cancer. The authors concluded that this combination has the potential to improve the outcomes for these patients.   Some background Extensive stage small-cell lung cancer (ES-SCLC) is...

Read More

The effect of FDG-PET imaging on patients with melanoma treated with immunotherapy.

Posted by on Sep 28, 2018 in Melanoma | 0 comments

In a nutshell The study looked at the use of FDG-PET imaging to assess long-term outcomes of treatment in patients with melanoma. Researchers found that FDG-PET imaging may be useful in predicting long-term outcomes of treatment in these patients. Some background Treatment for melanoma has vastly improved in recent years. Immunotherapies have improved...

Read More

Fulvestrant compared to aromatase inhibitors in post-menopausal women with HR+ advanced breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to look at the safety and effectiveness of fulvestrant (Faslodex) compared to aromatase inhibitors in post-menopausal women with hormone receptor-positive (HR+) breast cancer. The authors found that fulvestrant was a safe and effective treatment in these patients when compared to aromatase inhibitors. Some...

Read More

Everolimus and exemstane for treatment of HR+/HER2- advanced or metastatic breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

In a nutshell This study looked at the effectiveness and safety of a combination of two cancer drugs, everolimus (Afinitor) and exemestane (Aromasin), in women after menopause with advanced breast cancer. The authors found that these drugs were safe and effective in the treatment of these women. Some background Breast cancer is...

Read More

Pembrolizumab improves stage 3 melanoma outcomes

Posted by on Jun 4, 2018 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness of pembrolizumab (Keytruda) in the treatment of patients with stage 3 melanoma who underwent surgery. Researchers suggested that this drug is associated with longer recurrence-free survival with no new side effects. Some background The use of PD-1 antibodies, such as pembrolizumab, in patients...

Read More

Comparing two targeted therapy drugs – is gefitinib safer than erlotinib?

Posted by on May 21, 2018 in Lung cancer | 0 comments

In a nutshell This study compared two targeted therapy drugs gefitinib (Iressa) and erlotinib (Tarceva) in terms of effectiveness and safety at treating patients with advanced non-small-cell lung cancer. They concluded gefitinib was as effective as erlotinib but with fewer toxic side effects. Some background Current and newer treatment options...

Read More